Literature DB >> 26124808

The therapy of gefitinib towards breast cancer partially through reversing breast cancer biomarker arginine.

Dongmei Geng1, Dengjun Sun1, Liangming Zhang1, Weiwei Zhang1.   

Abstract

BACKGROUND: Breast cancer remains the leading reason of cancer death among women worldwide, and gefitinib is the efficient drug for breast cancer. AIMS: To use targeted metabolomics method to elucidate the therapeutic mechanism of gefitinib through profiling the amino acids.
METHODS: Healthy women (n=56) and women with breast cancer (n=60) were enrolled in Affiliated Yuhuangding hospital, medical college of Qingdao University from 2012-2014. API 3200 triple quadrupole mass spectrometer was used to analyze the serum samples.
RESULTS: The concentration of amino acids was compared between healthy women and women with breast cancers. Compared with the healthy women, the concentration of arginine in breast cancer women significantly decreased (p<0.0001). To show the representative capability of arginine towards the pathogenesis of breast cancers, the receiver operating characteristic (ROC) curve was drawn, and the area under the curve (AUC) was calculated to be 0.96 ± 0.02, indicating the high predictive capability of arginine for breast cancer . The reversing ability of gefitinib towards the level of arginine was further determined, and 1 month treatment of gefitinib (500 mg/day) significantly reversed the arginine level of breast cancer patients (p<0.0001).
CONCLUSION: The therapy of gefitinib towards breast cancer through reversing breast cancer biomarker arginine was demonstrated.

Entities:  

Keywords:  Breast cancer; arginine; gefitinib; metabolomics

Mesh:

Substances:

Year:  2015        PMID: 26124808      PMCID: PMC4480457          DOI: 10.4314/ahs.v15i2.36

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  8 in total

Review 1.  Amino acid network for the discrimination of native protein structures from decoys.

Authors:  Jianhong Zhou; Wenying Yan; Guang Hu; Bairong Shen
Journal:  Curr Protein Pept Sci       Date:  2014       Impact factor: 3.272

2.  Tryptophan as the fingerprint for distinguishing aggressiveness among breast cancer cell lines using native fluorescence spectroscopy.

Authors:  Lin Zhang; Yang Pu; Jianpeng Xue; Sebastião Pratavieira; Baogang Xu; Samuel Achilefu; Robert R Alfano
Journal:  J Biomed Opt       Date:  2014-03       Impact factor: 3.170

Review 3.  LC-MS-based metabolomics: an update.

Authors:  Zhong-Ze Fang; Frank J Gonzalez
Journal:  Arch Toxicol       Date:  2014-04-08       Impact factor: 5.153

4.  1H HR-MAS NMR spectroscopy of tumor-induced local metabolic "field-effects" enables colorectal cancer staging and prognostication.

Authors:  Beatriz Jiménez; Reza Mirnezami; James Kinross; Olivier Cloarec; Hector C Keun; Elaine Holmes; Robert D Goldin; Paul Ziprin; Ara Darzi; Jeremy K Nicholson
Journal:  J Proteome Res       Date:  2013-01-16       Impact factor: 4.466

5.  Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.

Authors:  Antonia Kalykaki; Sofia Agelaki; Galatea Kallergi; Alexandros Xyrafas; Dimitris Mavroudis; Vassilis Georgoulias
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-04       Impact factor: 3.333

6.  Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells.

Authors:  Fuming Qiu; Yun-Ru Chen; Xiyong Liu; Cheng-Ying Chu; Li-Jiuan Shen; Jinghong Xu; Shikha Gaur; Henry Jay Forman; Hang Zhang; Shu Zheng; Yun Yen; Jian Huang; Hsing-Jien Kung; David K Ann
Journal:  Sci Signal       Date:  2014-04-01       Impact factor: 8.192

Review 7.  MRS-based Metabolomics in Cancer Research.

Authors:  Tedros Bezabeh; Omkar B Ijare; Alexander E Nikulin; Rajmund L Somorjai; Ian Cp Smith
Journal:  Magn Reson Insights       Date:  2014-02-13

Review 8.  Toll-like receptor 9 in breast cancer.

Authors:  Jouko Sandholm; Katri S Selander
Journal:  Front Immunol       Date:  2014-07-22       Impact factor: 7.561

  8 in total
  5 in total

1.  Infectious diseases and chronic care in Africa.

Authors:  James K Tumwine
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

2.  Gefitinib suppresses cervical cancer progression by inhibiting cell cycle progression and epithelial-mesenchymal transition.

Authors:  Jianyun Zheng; Jianxin Yu; Min Yang; Li Tang
Journal:  Exp Ther Med       Date:  2019-07-09       Impact factor: 2.447

3.  L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.

Authors:  Yu Cao; Yonghui Feng; Yanjun Zhang; Xiaotong Zhu; Feng Jin
Journal:  BMC Cancer       Date:  2016-06-01       Impact factor: 4.430

4.  Theoretical Study on the Aggregation and Adsorption Behaviors of Anticancer Drug Molecules on Graphene/Graphene Oxide Surface.

Authors:  Pengyu Gong; Yi Zhou; Hui Li; Jie Zhang; Yuying Wu; Peiru Zheng; Yanyan Jiang
Journal:  Molecules       Date:  2022-10-10       Impact factor: 4.927

Review 5.  The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

Authors:  Michaela Poliaková; Daniel M Aebersold; Yitzhak Zimmer; Michaela Medová
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.